Polypurine reverse Hoogsteen hairpins as a gene therapy tool against survivin in human prostate cancer PC3 cells in vitro and in vivo

Biochemical Pharmacology

Volumn 86, Issue 11, 2013, Pages 1541-1554

  Rodríguez, Laura ^a   Villalobos, Xenia ^a   Dakhel, Sheila ^b   Padilla, Laura ^b   Hervas, Rosa ^b   Hernández, Jose Luis ^b   Ciudad, Carlos J ^a   Noé, Véronique ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b LEITAT TECHNOLOGICAL CENTER   (Spain)

Author keywords

Gene silencing; PPRH; Prostate cancer; Survivin; Xenograft

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; CASPASE 7; CD31 ANTIGEN; POLYPURINE REVERSE HOOGSTEEN HAIRPIN; SURVIVIN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GRAFT; CANCER SCREENING; CAPILLARY DENSITY; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GENE FUNCTION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRON; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

(3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIPHENYLTETRAZOLIUM BROMIDE; ANTISENSE OLIGONUCLEOTIDE; AODN; CASTRATION-RESISTANT PROSTATIC CANCER; CRPC; DOTAP; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EMSA; GENE SILENCING; MTT; N-[1-(2,3-DIOLEOYLOXY)PROPYL]-N,N,N-TRIMETHYLAMMONIUM METHYLSULFATE; NE; NUCLEAR EXTRACT; POLYPURINE REVERSE HOOGSTEEN HAIRPINS; PPRH; PPRHS; PROSTATE CANCER; SURVIVIN; XENOGRAFT;

ANIMALS; APOPTOSIS; BASE PAIRING; CELL LINE, TUMOR; CELL SURVIVAL; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENETIC THERAPY; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PURINE NUCLEOTIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887413555     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.09.013     Document Type: Article

References (46)

1. A. Avino, M. Frieden, J.C. Morales, B. Garcia de la Torre, R. Guimil Garcia, and F. Azorin Properties of triple helices formed by parallel-stranded hairpins containing 8-aminopurines Nucleic Acids Res 30 2002 2609 2619
2. S. Coma, V. Noe, R. Eritja, and C.J. Ciudad Strand displacement of double-stranded DNA by triplex-forming antiparallel purine-hairpins Oligonucleotides 15 2005 269 283
3. J.R. Goni, X. de la Cruz, and M. Orozco Triplex-forming oligonucleotide target sequences in the human genome Nucleic Acids Res 32 2004 354 360
4. M.C. de Almagro, S. Coma, V. Noe, and C.J. Ciudad Polypurine hairpins directed against the template strand of DNA knock down the expression of mammalian genes J Biol Chem 284 2009 11579 11589
5. M.C. de Almagro, N. Mencia, V. Noe, and C.J. Ciudad Coding polypurine hairpins cause target-induced cell death in breast cancer cells Hum Gene Ther 22 2011 451 463
6. S. Coma, V. Noe, C. Lavarino, J. Adan, M. Rivas, and M. Lopez-Matas Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis Oligonucleotides 14 2004 100 113
7. G. Ambrosini, C. Adida, and D.C. Altieri A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med 3 1997 917 921
8. M. Monzo, R. Rosell, E. Felip, J. Astudillo, J.J. Sanchez, and J. Maestre A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers J Clin Oncol 17 1999 2100 2104
9. K. Tanaka, S. Iwamoto, G. Gon, T. Nohara, M. Iwamoto, and N. Tanigawa Expression of survivin and its relationship to loss of apoptosis in breast carcinomas Clin Cancer Res 6 2000 127 134
10. H. Kawasaki, D.C. Altieri, C.D. Lu, M. Toyoda, T. Tenjo, and N. Tanigawa Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer Cancer Res 58 1998 5071 5074
11. R.A. Carrasco, N.B. Stamm, E. Marcusson, G. Sandusky, P. Iversen, and B.K. Patel Antisense inhibition of survivin expression as a cancer therapeutic Mol Cancer Ther 10 2011 221 232
12. C.D. Lu, D.C. Altieri, and N. Tanigawa Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas Cancer Res 58 1998 1808 1812
13. J. Kato, Y. Kuwabara, M. Mitani, N. Shinoda, A. Sato, and T. Toyama Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy Int J Cancer 95 2001 92 95
14. K. Satoh, K. Kaneko, M. Hirota, A. Masamune, A. Satoh, and T. Shimosegawa Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors Cancer 92 2001 271 278
15. H.S. Swana, D. Grossman, J.N. Anthony, R.M. Weiss, and D.C. Altieri Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer N Engl J Med 341 1999 452 453
16. Y. Saitoh, Y. Yaginuma, and M. Ishikawa Analysis of Bcl-2, Bax and Survivin genes in uterine cancer Int J Oncol 15 1999 137 141
17. H. Yoshida, O. Ishiko, T. Sumi, Y. Matsumoto, and S. Ogita Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas Int J Oncol 19 2001 537 542
18. C. Adida, C. Haioun, P. Gaulard, E. Lepage, P. Morel, and J. Briere Prognostic significance of survivin expression in diffuse large B-cell lymphomas Blood 96 2000 1921 1925
19. C. Adida, C. Recher, E. Raffoux, M.T. Daniel, A.L. Taksin, and P. Rousselot Expression and prognostic significance of survivin in de novo acute myeloid leukaemia Br J Haematol 111 2000 196 203
20. C. Adida, D. Berrebi, M. Peuchmaur, M. Reyes-Mugica, and D.C. Altieri Anti-apoptosis gene, survivin, and prognosis of neuroblastoma Lancet 351 1998 882 883
21. D. Grossman, J.M. McNiff, F. Li, and D.C. Altieri Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma J Invest Dermatol 113 1999 1076 1081
22. D. Grossman, J.M. McNiff, F. Li, and D.C. Altieri Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line Lab Invest 79 1999 1121 1126
23. B.Z. Carter, M. Milella, D.C. Altieri, and M. Andreeff Cytokine-regulated expression of survivin in myeloid leukemia Blood 97 2001 2784 2790
24. R. Gianani, E. Jarboe, D. Orlicky, M. Frost, J. Bobak, and R. Lehner Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa Hum Pathol 32 2001 119 125
25. A.I. Sarela, J.A. Guthrie, M.T. Seymour, E. Ride, P.J. Guillou, and D.S. O'Riordain Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer Br J Surg 88 2001 1352 1356
26. D.C. Altieri The molecular basis and potential role of survivin in cancer diagnosis and therapy Trends Mol Med 7 2001 542 547
27. A.K. Ramsay, and H.Y. Leung Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy Clin Sci (Lond) 117 2009 209 228
28. T. Nakahara, M. Takeuchi, I. Kinoyama, T. Minematsu, K. Shirasuna, and A. Matsuhisa YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts Cancer Res 67 2007 8014 8021
29. A.W. Tolcher, D.I. Quinn, A. Ferrari, F. Ahmann, G. Giaccone, and T. Drake A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer Ann Oncol 23 2012 968 973
30. P.J.C.P. Wiechno, J. Smok-Kalwat, J. Pikilel, D.H. Henry, and D.F. Christianson Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC) J Clin Oncol 29 2011 abstr 4592
31. H.X. Li, X.Y. Zhao, L. Wang, Y.S. Wang, B. Kan, and J.R. Xu Antitumor effect of mSurvivinThr34 - >Ala in murine colon carcinoma when administered intravenously Med Oncol 27 2010 1156 1163
32. X.C. Peng, L. Yang, L.P. Yang, Y.Q. Mao, H.S. Yang, and J.Y. Liu Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34 - >Ala mutant J Exp Clin Cancer Res 27 2008 46
33. F. Li, and D.C. Altieri Transcriptional analysis of human survivin gene expression Biochem J 344 Pt 2 1999 305 311
34. C.M. Perez-Stable, A. Pozas, and B.A. Roos A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer Mol Cell Endocrinol 167 2000 43 53
35. R. Boidot, F. Vegran, D. Jacob, S. Chevrier, M. Cadouot, and O. Feron The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism Oncogene 29 2010 2577 2584
36. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
37. R.A. Olie, A.P. Simoes-Wust, B. Baumann, S.H. Leech, D. Fabbro, and R.A. Stahel A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy Cancer Res 60 2000 2805 2809
38. M. Kappler, M. Bache, F. Bartel, M. Kotzsch, M. Panian, and P. Wurl Knockdown of survivin expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53 Cancer Gene Ther 11 2004 186 193
39. R. Blum, J. Jacob-Hirsch, G. Rechavi, and Y. Kloog Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis Mol Cancer Ther 5 2006 2337 2347
40. X. Ling, S. Cao, Q. Cheng, J.T. Keefe, Y.M. Rustum, and F. Li A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity PLoS One 7 2012 e45571
41. R. Xu, P. Zhang, J. Huang, S. Ge, J. Lu, and G. Qian Sp1 and Sp3 regulate basal transcription of the survivin gene Biochem Biophys Res Commun 356 2007 286 292
42. U.T. Sankpal, M. Abdelrahim, S.F. Connelly, C.M. Lee, R. Madero-Visbal, and J. Colon Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer Prostate 72 2012 1648 4858
43. J.B. Hansen, N. Fisker, M. Westergaard, L.S. Kjaerulff, H.F. Hansen, and C.A. Thrue SPC3042: a proapoptotic survivin inhibitor Mol Cancer Ther 7 2008 2736 2745
44. T. Kitano, H. Yoda, K. Tabata, M. Miura, M. Toriyama, and S. Motohashi Vitamin K3 analogs induce selective tumor cytotoxicity in neuroblastoma Biol Pharm Bull 35 2012 617 6123
45. A. Mukherjee, K. Huber, H. Evans, N. Lakhani, and S. Martin A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines Br J Pharmacol 151 2007 1167 1175
46. H. Holback, and Y. Yeo Intratumoral drug delivery with nanoparticulate carriers Pharm Res 28 2011 1819 1830